



www.genfit.com

GENFIT TO DISCLOSE THE PRINCIPAL RESULTS OF THE GFT505-210-5 CLINICAL TRIAL ON JULY 13th, 2011

THIS INTERNATIONAL PHASE II TRIAL AIMS TO ASSESS THE ANTI-DIABETIC
ACTION OF GFT505

Lille, France, and Cambridge, Mass., June 17th, 2011 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focused on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that it will present the principal results of the GFT505-210-5 clinical trial on July 13th, 2011.

This Phase II trial, launched in September 2010, studies the effect of 12 weeks of treatment of diabetic patients with 80 mg/day of GFT505, as assessed by the levels of the FDA- and EMEA-recognized efficacy marker, glycated hemoglobin (HbA1c).

The study includes 97 newly-diagnosed, treatment-naïve diabetic patients, with HbA1c levels between 6.8 and 9.5% at inclusion. This double-blind, randomized trial compares the effect of GFT505 treatment with placebo on HbA1c levels (1:1 patient ratio). The secondary endpoints include glucose homeostasis parameters (fasting glycemia, insulin, HOMA-IR, pro-insulin, C-peptide, OGTT), plasma lipid parameters (triglycerides, HDL-cholesterol, LDL-cholesterol, apolipoproteins), and inflammatory markers.

Dr. Rémy Hanf, Executive VP Product Development at GENFIT, declared: *«We are impatient to publish the first clinical results of this crucial study for our leading drug candidate. Besides the clinical value of GFT505, already recognized for dyslipidemia and the pro-inflammatory state, its efficacy on HbA1c, together with its exemplary safety profile, should provide it with a unique position in the treatment of Type 2 diabetes, and bring a new therapeutic response to this disease with major unmet medical needs.»*

About the treatment of prediabetes and diabetes:

The worldwide epidemic of obesity forecasts a parallel increase in the prevalence of type 2 diabetes and associated complications. According to the WHO, this “epidemic disease” could affect up to 300 million people by 2025 whereas they were only 30 million in 1985. Thus, the prevention and treatment of micro and macro-vascular diseases associated with prediabetes and diabetes are considered as worldwide public health issues by both academic societies (IAS, ADA, EASD) and health organizations (WHO, FDA, EMEA). Prediabetic and diabetic patients suffer from overlapping disorders (high blood pressure, dyslipidemia, insulin resistance, inflammation) which increase the risk of developing related micro and macro-vascular diseases: myocardial infarction, stroke, retinopathy, kidney disease, diabetic foot, or arteritis. Insufficient diagnostic tools and current treatments do not totally cover this global medical need. At present, even treated patients remain at high risk of developing vascular diseases. In particular, atherogenic dyslipidemia (characterized by low plasma levels of good cholesterol (HDL-C) and high level of triglycerides), the pro-inflammatory and oxidative states, and alteration of glucose metabolism are promising therapeutic targets for the medical management of prediabetic and diabetic populations.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive

solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, ...), to address these major public health concerns and their unmet medical needs. GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
+33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr